Last reviewed · How we verify
Bimatoprost Vehicle
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Bimatoprost Vehicle |
|---|---|
| Sponsor | Allergan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bimatoprost binds to prostaglandin F (FP) receptors on the ciliary muscle bundle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This increased outflow reduces intraocular pressure, making it effective for glaucoma and ocular hypertension. The vehicle formulation is the inactive carrier system used to deliver bimatoprost to the eye.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris hyperpigmentation
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Foreign body sensation
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension (PHASE3)
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis (PHASE3)
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis (PHASE3)
- Bimatoprost for the Treatment of Eyebrow Hypotrichosis (PHASE3)
- Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension (NA)
- Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost Vehicle CI brief — competitive landscape report
- Bimatoprost Vehicle updates RSS · CI watch RSS
- Allergan portfolio CI